GlaxoSmithKline

NEWS

Moncef Slaoui Will Quit Operation Warp Speed if Politics Plays Role in Vaccine Approval

When Moncef Slaoui was tapped to helm Operation Warp Speed, he sought confirmation that politics would not play a role in driving certain treatments through an approval process without the proper supporting scientific data to back it up.

September 4, 2020

2 min read

Alex Keown

Drug Development

Biopharma Update on the Novel Coronavirus: September 4

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 4, 2020.

September 3, 2020

3 min read

BioSpace Editorial Staff

Job Trends

A London AI Hub, a Facility Bigger than the Louvre, Are Among the Newest Footprint Expansions in the Life Sciences Industry

GlaxoSmithKline has opened a new $13 million research hub in London focused on artificial intelligence.

September 3, 2020

2 min read

Alex Keown

Business

Sanofi, GSK Move COVID-19 Vaccine Candidate Into the Clinic, Expect Data by December

Months after forging a development partnership for a COVID-19 vaccine, GlaxoSmithKline and Sanofi are moving their adjuvanted vaccine candidate into the clinic.

September 3, 2020

2 min read

Alex Keown

Drug Development

Vir Bio and GSK Join the Race for a COVID-19 Monoclonal Antibody Therapy

Vir Biotechnology and GlaxoSmithKline dosed the first patient last week in a Phase II/III clinical trial of VIR-7831, a fully human monoclonal antibody against COVID-19.

August 31, 2020

3 min read

Mark Terry

Policy

Biopharma Update on the Novel Coronavirus: August 31

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 31, 2020.

August 31, 2020

2 min read

BioSpace Editorial Staff

FDA

FDA Approves GSK’s Blenrep as Fourth-Line Multiple Myeloma Monotherapy Treatment

Blenrep is GSK’s second regulatory approval in four months. GlaxoSmithKline is once again making its mark as an oncology-focused pharmaceutical company.

August 6, 2020

3 min read

Alex Keown

Business

GSK and Sanofi Strike $2.1 Billion Deal with U.S. Government for 100 Million Doses of COVID-19 Vaccine

GlaxoSmithKline and Sanofi struck a $2.1 billion deal with the U.S. government’s Operation Warp Speed program to supply an initial 100 million doses of a COVID-19 vaccine candidate under development by the two companies.

July 31, 2020

2 min read

Alex Keown